Clin Oncol | Volume 7, Issue 1 | Research Article | Open Access
Shen Y1, Bai J1, Yang Y1, Wang F1 and He A1,2*
1Department of Hematology, Second Affiliated Hospital, Xi’an Jiaotong University, China
2National-Local Joint Engineering Research Center of Biodiagnostics and Biotherapy, Xi’an, Shaanxi, China
Objectives: Acute Myeloid Leukemia (AML) patients undergoing intensive chemotherapy have a high risk for infection. Reportedly Intravenous Immunoglobulin (IVIg) could improve immune function and significantly reduce febrile episodes and febrile days in pediatric patients with AML and infection. To investigate the adjunct therapeutic effect of IVIg on adult patients with AML, we
carried out this study.
Methods: We retrospectively analyzed 138 adult patients with AML who had neutropenia and infection after chemotherapy. Among them, 62 patients got IVIg treatment and 76 did not (serving as controls).
Results: Between two groups there were no differences in the French-American-British classification (FAB) classification, risk status, therapy stage, chemotherapy, duration of neutropenia, site of infection and central venous catheter. But febrile days were significantly decreased in IVIg group relative to the control group (P<0.001).
Discussion: This suggests that IVIg may be an effective adjunct therapy for adult patients with AML who have neutropenia and infection after intensive chemotherapy.
Intravenous Immunoglobin; Febrile Days; Neutropenia; Infection; Acute Myeloid Leukemia
Shen Y, Bai J, Yang Y, Wang F, He A. Intravenous Immunoglobulin: AnEffective Adjunct Therapy for Acute Myeloid Leukemia Patients with Neutropenia and Infection. Clin Oncol. 2022;7:1971..